Discover Our Peptide Portfolio In 2023, the FDA reviewed several peptides nominated for compounding and placed many on the 503A Category 2 list.[3] Then in 2024, the agency cited limited clinical safety data, along with concerns about immunogenicity (how the immune system might respond) and dosing variability.[4] It was a precautionary decision, and precaution is an important part of regulatory oversight
Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model
an independently verifiable Janoshik unique key is evidence
Yes, most lab work is completed directly at our Toms River clinic, allowing for faster results and a more streamlined experience
If you have low vitamin B12 levels or deficiency, consult with your doctor about whether B12 shots are good for you or not
High-dose B12 can mask underlying conditions that need medical attention